National Academies Press: OpenBook
« Previous: 7 Panelists' and Stakeholders' Perspectives
Suggested Citation:"References." Institute of Medicine. 2013. The Economics of Genomic Medicine: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18276.


ACS (American Cancer Society). 2012. Cancer facts and figures 2012. Atlanta, GA: American Cancer Society.

Ashley, E. A., A. J. Butte, M. T. Wheeler, R. Chen, T. E. Klein, F. E. Dewey, J. T. Dudley, K. E. Ormond, A. Pavlovic, A. A. Morgan, D. Pushkarev, N. F. Neff, L. Hudgins, L. Gong, L. M. Hodges, D. S. Berlin, C. F. Thorn, K. Sangkuhl, J. M. Hebert, M. Woon, H. Sagreiya, R. Whaley, J. W. Knowles, M. F. Chou, J. V. Thakuria, A. M. Rosenbaum, A. W. Zaranek, G. M. Church, H. T. Greely, S. R. Quake, and R. B. Altman. 2010. Clinical assessment incorporating a personal genome. Lancet 375(9725):1525-1535.

Atherly, A. J., and D. R. Camidge. 2012. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. British Journal of Cancer 106(6):1100-1106.

Balak, M. N., Y. Gong, G. J. Riely, R. Somwar, A. R. Li, M. F. Zakowski, A. Chiang, G. Yang, O. Ouerfelli, M. G. Kris, M. Ladanyi, V. A. Miller, and W. Pao. 2006. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical Cancer Research 12(21):6494-6501.

Ball, M. P., J. V. Thakuria, A. W. Zaranek, T. Clegg, A. M. Rosenbaum, X. Wu, M. Angrist, J. Bhak, J. Bobe, M. J. Callow, C. Cano, M. F. Chou, W. K. Chung, S. M. Douglas, P. W. Estep, A. Gore, P. Hulick, A. Labarga, J. H. Lee, J. E. Lunshof, B. C. Kim, J. I. Kim, Z. Li, M. F. Murray, G. B. Nilsen, B. A. Peters, A. M. Raman, H. Y. Rienhoff, K. Robasky, M. T. Wheeler, W. Vandewege, D. B. Vorhaus, J. L. Yang, L. Yang, J. Aach, E. A. Ashley, R. Drmanac, S. J. Kim, J. B. Li, L. Peshkin, C. E. Seidman, J. S. Seo, K. Zhang, H. L. Rehm, and G. M. Church. 2012. A public resource facilitating clinical use of genomes. Proceedings of the National Academy of Sciences of the United States of America 109(30):11920-11927.

Basu, A., and D. Meltzer. 2007. Value of information on preference heterogeneity and individualized care. Medical Decision Making 27(2):112-127.

Suggested Citation:"References." Institute of Medicine. 2013. The Economics of Genomic Medicine: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18276.

Bean, J., G. J. Riely, M. Balak, J. L. Marks, M. Ladanyi, V. A. Miller, and W. Pao. 2008. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clinical Cancer Research 14(22):7519-7525.

Beckman, M. G., W. C. Hooper, S. E. Critchley, and T. L. Ortel. 2010. Venous thromboembolism: A public health concern. American Journal of Preventive Medicine 38(4 Suppl):S495-S501.

Bradbury, P. A., D. Tu, L. Seymour, P. K. Isogai, L. Zhu, R. Ng, N. Mittmann, M. S. Tsao, W. K. Evans, F. A. Shepherd, N. B. Leighl, and the NCIC Clinical Trials Working Group on Economic Analysis. 2010. Economic analysis: Randomized placebo-controlled clinical trial of erlotinib in advanced non-small-cell lung cancer. Journal of the National Cancer Institute 102(5):298-306.

Bristol-Myers Squibb. 2010. Prescribing information for Coumadin (warfarin sodium). Princeton, NJ: Bristol-Myers Squibb. (accessed March 19, 2013).

Dentali, F., A. P. Sironi, W. Ageno, S. Turato, C. Bonfanti, F. Frattini, S. Crestani, and M. Franchini. 2012. Non-O blood type is the commonest genetic risk factor for VTE: Results from a meta-analysis of the literature. Seminars in Thrombosis and Hemostasis 38(5):535-548.

Dewey, F. E., R. Chen, S. P. Cordero, K. E. Ormond, C. Caleshu, K. J. Karczewski, M. Whirl-Carrillo, M. T. Wheeler, J. T. Dudley, J. K. Byrnes, O. E. Cornejo, J. W. Knowles, M. Woon, K. Sangkuhl, L. Gong, C. F. Thorn, J. M. Hebert, E. Capriotti, S. P. David, A. Pavlovic, A. West, J. V. Thakuria, M. P. Ball, A. W. Zaranek, H. L. Rehm, G. M. Church, J. S. West, C. D. Bustamante, M. Snyder, R. B. Altman, T. E. Klein, A. J. Butte, and E. A. Ashley. 2011. Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. PLoS Genetics 7(9):e1002280.

Epstein, R. S., T. P. Moyer, R. E. Aubert, D. J. O’Kane, F. Xia, R. R. Verbrugge, B. F. Gage, and J. R. Teagarden. 2010. Warfarin genotyping reduces hospitalization rates: Results from the MM-WES (Medco-Mayo Warfarin Effectiveness Study). Journal of the American College of Cardiology 55(25):2804-2812.

Flowers, C. R., and D. Veenstra. 2004. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics 22(8):481-493.

Grody, W. W., J. H. Griffin, A. K. Taylor, B. R. Korf, J. A. Heit, and the American College of Medical Genetics Factor V Working Group. 2001. American College of Medical Genetics consensus statement on Factor V Leiden mutation testing. Genetics in Medicine 3(2):139-148.

Grosse, S. D., S. Wordsworth, and K. Payne. 2008. Economic methods for valuing the outcomes of genetic testing: Beyond cost-effectiveness analysis. Genetics in Medicine 10(9):648-654.

Hampel, H., W. L. Frankel, E. Martin, M. Arnold, K. Khanduja, P. Kuebler, M. Clendenning, K. Sotamaa, T. Prior, J. A. Westman, J. Panescu, D. Fix, J. Lockman, J. LaJeunesse, I. Comeras, and A. de la Chapelle. 2008. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. Journal of Clinical Oncology 26(35):5783-5788.

Jick, H., D. Slone, B. Westerholm, W. H. Inman, M. P. Vessey, S. Shapiro, G. P. Lewis, and J. Worcester. 1969. Venous thromboembolic disease and ABO blood type. A cooperative study. Lancet 1(7594):539-542.

Kelly, K., J. Crowley, P. A. Bunn, Jr., C. A. Presant, P. K. Grevstad, C. M. Moinpour, S. D. Ramsey, A. J. Wozniak, G. R. Weiss, D. F. Moore, V. K. Israel, R. B. Livingston, and D. R. Gandara. 2001. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. Journal of Clinical Oncology 19(13):3210-3218.

Suggested Citation:"References." Institute of Medicine. 2013. The Economics of Genomic Medicine: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18276.

Kris, M. G., R. B. Natale, R. S. Herbst, T. J. Lynch, Jr., D. Prager, C. P. Belani, J. H. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, K. S. Albain, D. Cella, M. K. Wolf, S. D. Averbuch, J. J. Ochs, and A. C. Kay. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: A randomized trial. Journal of the American Medical Association 290(16):2149-2158.

Ladabaum, U., G. Wang, J. Terdiman, A. Blanco, M. Kuppermann, C. R. Boland, J. Ford, E. Elkin, and K. A. Phillips. 2011. Strategies to identify the Lynch syndrome among patients with colorectal cancer: A cost-effectiveness analysis. Annals of Internal Medicine 155(2):69-79.

Lockwood, C., G. Wendel, and Committee on Practice Bulletins—Obstetrics. 2011. Practice bulletin no. 124: Inherited thrombophilias in pregnancy. Obstetrics and Gynecology 118(3):730-740.

Mallal, S., E. Phillips, G. Carosi, J. M. Molina, C. Workman, J. Tomazic, E. Jagel-Guedes, S. Rugina, O. Kozyrev, J. F. Cid, P. Hay, D. Nolan, S. Hughes, A. Hughes, S. Ryan, N. Fitch, D. Thorborn, A. Benbow, and PREDICT-1 Study Team. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. New England Journal of Medicine 358(6):568-579.

Maron, B. J., M. S. Maron, and C. Semsarian. 2012. Genetics of hypertrophic cardiomyopathy after 20 years: Clinical perspectives. Journal of the American College of Cardiology 60(8):705-715.

Martin, J. A., B. E. Hamilton, S. J. Ventura, M. J. Osterman, E. C. Wilson, and T. J. Mathews. 2012. Births: Final data for 2010. Atlanta, GA: Centers for Disease Control and Prevention.

Medalie, J. H., C. Levene, C. Papier, U. Goldbourt, F. Dreyfuss, D. Oron, H. Neufeld, and E. Riss. 1971. Blood groups, myocardial infarction and angina pectoris among 10,000 adult males. New England Journal of Medicine 285(24):1348-1353.

Mok, T. S., Y. L. Wu, S. Thongprasert, C. H. Yang, D. T. Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, J. J. Yang, B. Chewaskulyong, H. Jiang, E. L. Duffield, C. L. Watkins, A. A. Armour, and M. Fukuoka. 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 361(10):947-957.

Neel, J. V. 1949. The inheritance of sickle cell anemia. Science 110(2846):64-66.

Pao, W., V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, and H. Varmus. 2004. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the National Academy of Sciences of the United States of America 101(36):13306-13311.

Pauling, L., H. A. Itano, S. J. Singer, and I. C. Wells. 1949. Sickle cell anemia: A molecular disease. Science 110(2865):543-548.

Plevritis, S. K., A. W. Kurian, B. M. Sigal, B. L. Daniel, D. M. Ikeda, F. E. Stockdale, and A. M. Garber. 2006. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. Journal of the American Medical Association 295(20):2374-2384.

Ramsey, S. D., D. L. Veenstra, L. P. Garrison, Jr., R. Carlson, P. Billings, J. Carlson, and S. D. Sullivan. 2006. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. American Journal of Managed Care 12(4):197-202.

Regier, D. A., J. M. Friedman, N. Makela, M. Ryan, and C. A. Marra. 2009. Valuing the benefit of diagnostic testing for genetic causes of idiopathic developmental disability: Willingness to pay from families of affected children. Clinical Genetics 75(6):514-521.

Suggested Citation:"References." Institute of Medicine. 2013. The Economics of Genomic Medicine: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18276.

Riess, J. W., and H. A. Wakelee. 2012. Metastatic non-small-cell lung cancer management: Novel targets and recent clinical advances. Clinical Advances in Hematology and Oncology 10(4):226-234.

Roach, J. C., G. Glusman, A. F. Smit, C. D. Huff, R. Hubley, P. T. Shannon, L. Rowen, K. P. Pant, N. Goodman, M. Bamshad, J. Shendure, R. Drmanac, L. B. Jorde, L. Hood, and D. J. Galas. 2010. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 328(5978):636-639.

Russell, R. B., N. S. Green, C. A. Steiner, S. Meikle, J. L. Howse, K. Poschman, T. Dias, L. Potetz, M. J. Davidoff, K. Damus, and J. R. Petrini. 2007. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics 120(1):e1-e9.

Schiller, J. H., D. Harrington, C. P. Belani, C. Langer, A. Sandler, J. Krook, J. Zhu, D. H. Johnson, and the Eastern Cooperative Oncology Group. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine 346(2):92-98.

Shah, N. R., and M. B. Bracken. 2000. A systematic review and meta-analysis of prospective studies on the association between maternal cigarette smoking and preterm delivery. American Journal of Obstetrics and Gynecology 182(2):465-472.

Shiffman, D., K. Slawsky, L. Fusfeld, J. J. Devlin, and T. F. Goss. 2012. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease. Clinical Therapeutics 34(6):1387-1394.

Silverstein, M. D., J. A. Heit, D. N. Mohr, T. M. Petterson, W. M. O’Fallon, and L. J. Melton III. 1998. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Archives of Internal Medicine 158(6):585-593.

Sode, B. F., K. H. Allin, M. Dahl, F. Gyntelberg, and B. G. Nordestgaard. 2013. Risk of venous thromboembolism and myocardial infarction associated with Factor V Leiden and prothrombin mutations and blood type. Canadian Medical Association Journal 185(5):E229-E237.

Srinivasan, B. S., E. A. Evans, J. Flannick, A. S. Patterson, C. C. Chang, T. Pham, S. Young, A. Kaushal, J. Lee, J. L. Jacobson, and P. Patrizio. 2010. A universal carrier test for the long tail of Mendelian disease. Reproductive Biomedicine Online 21(4):537-551.

Vandenbroucke, J. P., J. Rosing, K. W. Bloemenkamp, S. Middeldorp, F. M. Helmerhorst, B. N. Bouma, and F. R. Rosendaal. 2001. Oral contraceptives and the risk of venous thrombosis. New England Journal of Medicine 344(20):1527-1535.

Wang, X., B. Zuckerman, C. Pearson, G. Kaufman, C. Chen, G. Wang, T. Niu, P. H. Wise, H. Bauchner, and X. Xu. 2002. Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. Journal of the American Medical Association 287(2):195-202.

Suggested Citation:"References." Institute of Medicine. 2013. The Economics of Genomic Medicine: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18276.
Page 73
Suggested Citation:"References." Institute of Medicine. 2013. The Economics of Genomic Medicine: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18276.
Page 74
Suggested Citation:"References." Institute of Medicine. 2013. The Economics of Genomic Medicine: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18276.
Page 75
Suggested Citation:"References." Institute of Medicine. 2013. The Economics of Genomic Medicine: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18276.
Page 76
Next: Appendix A: Workshop Agenda »
The Economics of Genomic Medicine: Workshop Summary Get This Book
Buy Paperback | $42.00 Buy Ebook | $33.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The sequencing of the human genome and the identification of links between specific genetic variants and diseases have led to tremendous excitement over the potential of genomics to direct patient treatment toward more effective or less harmful interventions. Still, the use of whole genome sequencing challenges the traditional model of medical care where a test is ordered only when there is a clear indication for its use and a path for downstream clinical action is known. This has created a tension between experts who contend that using this information is premature and those who believe that having such information will empower health care providers and patients to make proactive decisions regarding lifestyle and treatment options.

In addition, some stakeholders are concerned that genomic technologies will add costs to the health care system without providing commensurate benefits, and others think that health care costs could be reduced by identifying unnecessary or ineffective treatments. Economic models are frequently used to anticipate the costs and benefits of new health care technologies, policies, and regulations. Economic studies also have been used to examine much more specific issues, such as comparing the outcomes and cost effectiveness of two different drug treatments for the same condition. These kinds of analyses offer more than just predictions of future health care costs. They provide information that is valuable when implementing and using new technologies. Unfortunately, however, these economic assessments are often limited by a lack of data on which to base the examination. This particularly affects health economics, which includes many factors for which current methods are inadequate for assessing, such as personal utility, social utility, and patient preference.

To understand better the health economic issues that may arise in the course of integrating genomic data into health care, the Roundtable on Translating Genomic-Based Research for Health hosted a workshop in Washington, DC, on July 17-18, 2012, that brought together economists, regulators, payers, biomedical researchers, patients, providers, and other stakeholders to discuss the many factors that may influence this implementation. The workshop was one of a series that the roundtable has held on this topic, but it was the first focused specifically on economic issues. The Economics of Genomic Medicine summarizes this workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook,'s online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!